Participating Companies

Achilles Therapeutics
cNeT (clo­n­al neoanti­gen) pro­cess builds on TILs, com­bined with abil­i­ty to iden­ti­fy pt-spe­cif­ic clo­n­al neoanti­gens and gen­er­ate per­so­n­al­ized T-cell ther­a­pies. Sep19 GBP100 mil­lion Se­ries B w/ RA, Syn­co­na, For­bion, In­vus, Per­cep­tive + Red­mile. [more in­for­ma­tion]
AM-Pharma B.V.
Raised $195M in equi­ty and debt in 2019/2020 af­ter re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed ro­bust sig­ni­f­i­cant im­prove­ment of 40%+ OS in re­cAP group. TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts Q1 2022. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023, or as ear­ly as 2022 based on in­ter­im anal­y­s­es. [more in­for­ma­tion]
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Arvelle Therapeutics
Arvelle is head­quar­tered in Switz­er­land and re­ceived start-up fi­nanc­ing of $207.8 mil­lion, one of the largest ini­tial fi­nanc­ing com­mit­ments for a Eu­ro­pean-fo­cused bio­phar­ma­ceu­ti­cal com­pany, with in­vest­ments from a glob­al syn­di­cate in­clud­ing No­vaQuest Cap­i­tal Ma­n­age­ment, BRV Cap­i­tal Ma­n­age­ment, LSP, H.I.G. [more in­for­ma­tion]
AsclepiX Therapeutics
Oph­thal­mol­o­gy com­pany us­ing com­pu­ta­tio­n­al bi­ol­o­gy to iden­ti­fy po­tent pep­tide reg­u­la­tors of vas­cu­lar home­os­ta­sis. The lead clin­i­cal can­di­date, in­te­grin reg­u­lat­ing pep­tide AX­T107 (ger­sizan­gi­tide), has a nov­el mech­anism of ac­tion that in­hibits neo­vas­cu­lariza­tion, re­duces vas­cu­lar perme­a­bil­i­ty and sup­press­es in­flam­ma­tion. In June 2020, Per­cep­tive Xon­toge­ny Ven­ture Fund led the $35 mil­lion Se­ries A fi­nanc­ing with par­ti­ci­pa­tion from ex­ist­ing in­ves­tors Rapha Cap­i­tal Ma­n­age­ment and Bar­er & Son Cap­i­tal. [more in­for­ma­tion]
Axial Biotherapeutics, Inc.
The com­pany's bio­ther­a­peu­tics prod­ucts har­ness the gut-brain axis to de­vel­op nov­el Cen­tral Ner­vous Sys­tem (CNS) Ther­a­peu­tics to im­prove the qual­i­ty of life for peo­ple with CNS dis­eas­es and di­s­or­ders, pro­vid­ing med­i­cal pro­fes­sio­n­als and health­care in­sti­tu­tions with a new ap­proach for di­ag­nos­ing and treat­ing PD and ASD and po­ten­tial­ly other CNS dis­eas­es. [more in­for­ma­tion]
Cadent Therapeutics
Ca­dent Ther­a­peu­tics is cre­at­ing break­through ther­a­pies for the treat­ment of move­ment di­s­or­ders and cog­ni­tive im­pair­ment. The com­pany has an ex­clu­sive li­cense and col­lab­o­ra­tion agree­ment with No­var­tis to de­vel­op a neg­a­tive al­los­ter­ic mo­d­u­la­tor, now in Phase 1 clin­i­cal studies for the treat­ment of treat­ment re­sis­tant de­pres­sion. [more in­for­ma­tion]
Carisma Therapeutics Inc.
- CARIS­MA Ther­a­peu­tics Inc. is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a dif­fer­en­ti­at­ed and pro­pri­e­tary cell ther­a­py plat­form fo­cused on en­gi­neered macrophages, cells that play a cru­cial role in both the in­nate and adap­tive im­mune re­sponse. CARIS­MA Ther­a­peu­tics is head­quar­tered in Philadel­phia, PA. [more in­for­ma­tion]
Cerebral Therapeutics
The com­pany's ther­a­pies uti­l­ize re­for­mu­lat­ed off-pa­tent drugs de­liv­ered to the ven­tri­cles of the brain in or­der to by­pass the blood-brain bar­ri­er, en­abling its clients to re­ceive a re­li­able ap­proach of treat­ing neu­ro­log­i­cal dis­eas­es for which oral in­fused medicines are not able to achieve ad­e­qu­ate con­trol. [more in­for­ma­tion]
Cerecin's Alzheimer's dis­ease pro­gram is one of the few pre­ci­sion medicines in de­vel­op­ment, ad­dress­ing a spe­cif­ic ge­net­ic sub-group, the non-car­ri­ers of the APOE4 al­lele (ac­counts for 45-85% of AD pa­tients). [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia, astig­ma­tism, my­opia, my­opia pro­gres­sion) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Pres­by­opia con­tact lens 510k sub­mis­sion 2022. Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
Commodore Capital
Com­mo­dore Cap­i­tal be­lieves that we are in the ear­ly stages of a ma­jor in­no­va­tion cy­cle in bio­phar­ma­ceu­ti­cals. Im­por­tant sci­en­tif­ic dis­cov­eries are trans­lat­ing in­to ma­jor clin­i­cal break­throughs, en­abled by the ad­vent of nov­el ther­a­peu­tic mo­dal­i­ties such as ge­net­ic medicines and cel­lu­lar ther­a­pies. [more in­for­ma­tion]
Decibel Therapeutics
The com­pany's ther­a­peu­tics have pro­vid­ed in­sights in­to the link be­tween hear­ing dys­func­tion and in­n­er ear pathol­o­gy and it has ca­pa­bil­i­ties to en­com­pass an­i­mal mod­els, drug de­liv­ery to the in­n­er ear, imag­ing, in­n­er ear PK/PD mod­el­ing and mea­sure­ment, bioin­for­mat­ics, ge­net­ics and tar­get iden­ti­fi­ca­tion, en­abling pa­tients to ex­pe­ri­ence hear­ing loss ther­a­pies with dif­fer­ent forms of hear­ing di­s­or­ders for their re­cov­ery. [more in­for­ma­tion]
DTx Pharma
De­vel­op­er of an RNA-based ther­a­peu­tics de­signed to aid in per­so­n­al­ized treat­ment across most ther­a­peu­tic ar­eas. The com­pany's tech­nol­o­gy en­ables ef­fi­cient de­liv­ery of nu­cle­ic acid drugs to tis­sues through­out the body, en­abling health­care providers to de­liv­er oli­gos in vi­vo at ther­a­peu­ti­cal­ly rel­e­vant dos­es that work in many cell types in­clud­ing neu­rons, en­dothe­lial and T cells. [more in­for­ma­tion]
eGenesis Inc.
eGe­n­e­sis has a clear path for­ward to ad­vance an ini­tial prod­uct to the clin­ic for at-risk pa­tients on the tran­s­plant wait­list, with the longer-term po­ten­tial of ad­dress­ing a broad­er pop­u­la­tion and ex­pand­ing the ap­pli­ca­bil­i­ty of tran­s­plan­ta­tion in­to other are­nas such as cell ther­a­py. [more in­for­ma­tion]
En­terome is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing nov­el drugs based on its unique abil­i­ty to de-code molec­u­lar in­ter­ac­tions in the gut mi­cro­biome im­pact­ing hu­man health. En­terome’s suc­cess is based on its unique abil­i­ty to iden­ti­fy small pro­teins and pep­tides from gut bac­te­ria that can de­liv­er a ther­a­peu­tic ben­e­fit in hu­mans. [more in­for­ma­tion]
Escient Pharmaceuticals
Es­cient is led by an ex­pe­ri­enced team of biotech­nol­o­gy en­trepreneurs with spe­cif­ic ex­per­tise in GPCR drug dis­cov­ery and de­vel­op­ment, and fund­ed by top-ti­er life sci­ence in­ves­tors, in­clud­ing The Col­umn Group, 5AM Ven­tures, Os­age Uni­ver­si­ty Part­n­ers and Al­ti­tude Life Sci­ence Ven­tures. [more in­for­ma­tion]
Evox Therapeutics
Ex­o­some-based drugs have the po­ten­tial to ad­dress some of the lim­i­ta­tions of pro­tein, anti­body and nu­cle­ic acid-based ther­a­pies by en­abling de­liv­ery to cells and tis­sues that are cur­rent­ly out of reach us­ing other drug de­liv­ery tech­nolo­gies, and Evox is lead­ing the de­vel­op­ment within this emerg­ing ther­a­peu­tic space. [more in­for­ma­tion]
Glycostem Therapeutics
Gly­costem Ther­a­peu­tics is a Dutch biotech com­pany. Gly­costem Ther­a­peu­tics is the trade name of the le­gal en­ti­ty IPD Ther­a­peu­tics BV, which has been estab­lished in De­cem­ber 2007. Gly­costem Ther­a­peu­tics has de­vel­oped the world's first GMP com­pliant NK-cell plat­form that is ready for in­dus­trial scale-up. [more in­for­ma­tion]
Imago BioSciences
The com­pany's ther­a­peu­tics are de­vel­oped for neo­plas­tic dis­eas­es of the bone mar­row for al­ter­ing gene ex­pres­sion pat­terns by tar­get­ing en­zymes that reg­u­late gene tran­scrip­tion, en­abling med­i­cal prac­ti­tion­ers to im­prove the ma­n­age­ment of pro­lif­er­a­tive dis­eas­es of the bone mar­row and mo­d­u­la­tion of the im­mune sys­tem. [more in­for­ma­tion]
Impact Therapeutics Inc
IM­PACT Ther­a­peu­tics is a pri­vate­ly held clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany and ded­i­cat­ed to the dis­cov­ery and de­vel­op­ment of tar­get­ed an­ti-can­cer ther­a­peu­tics based on syn­thet­ic lethal­i­ty. IM­P7068 is a nov­el Wee1 in­hibi­tor dis­cov­ered and de­vel­oped by IM­PACT Ther­a­peu­tics, with world­wide in­tel­lec­tu­al prop­er­ty, part of in-house DDR franchise. [more in­for­ma­tion]
InCarda Therapeutics
The com­pany will short­ly be­gin Phase 3 trials for the lead prod­uct, In­Rhythm (in­haled fle­cainide), which will be the first and on­ly treat­ment in the world to al­low parox­ys­mal atrial fib­ril­la­tion pa­tients to quick­ly and safe­ly re­solve acute epi­sodes them­selves, any­time, any­where. [more in­for­ma­tion]
In­vetx is build­ing the world’s pre­mi­er biotech­nol­o­gy plat­form for pro­tein-based ther­a­peu­tics in an­i­mal health to trans­form stan­dards of care in ve­t­eri­nary medicine. The In­vetx team of high­ly ex­pe­ri­enced R&D lead­ers from both hu­man biotech and an­i­mal health is sup­port­ed by best-in-class biotech­nol­o­gy part­n­ers and an ex­ten­sive net­work of in­dus­try ex­perts, ve­t­eri­nary sci­en­tists and clini­cians. In­vetx is a pri­vate com­pany head­quar­tered in Bos­ton, Mas­sachusetts. [more in­for­ma­tion]
ISA Pharmaceuticals BV
is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]
De­vel­op­er of cell-based tech­nol­o­gy in­tend­ed to cure re­tini­tis pig­men­tosa. The com­pany's ther­a­py used reti­nal pro­gen­i­tor cells can se­crete growth fac­tors to res­cue da­m­aged reti­nal cells which helps in treat­ing a de­gen­er­a­tive eye dis­ease that ul­ti­mate­ly caus­es blind­ness en­abling, pa­tients af­flict­ed by con­di­tions that lead to blind­ness, pre­serve and re­s­tore sight. [more in­for­ma­tion]
Jna­na Ther­a­peu­tics is a biotech­nol­o­gy com­pany fo­cused on mo­d­u­lat­ing cel­lu­lar metabolism by open­ing the so­lute car­ri­er (SLC) fam­i­ly of metabo­lite tran­s­porters as a tar­get class to de­vel­op trans­for­ma­tio­n­al ther­a­peu­tics. [more in­for­ma­tion]
KAHR is de­vel­op­ing nov­el im­muno-on­col­o­gy fu­sion pro­teins. DSP107, is a CD47-41BB tar­get­ing com­pound aimed at tar­get­ing can­cer cells' in­nate de­fens­es and ac­ti­vat­ing lo­cal­ized re­sponse. Ac­ti­vat­ed path­ways in­clude in­nate and adap­tive im­mu­ni­ty. [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $360M+ deal with Ge­nen­tech for KCP506, Ph1 non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Kleo Pharmaceuticals
They are how­ev­er much low­er in molec­u­lar weight than ther­a­peu­tic anti­bodies and there­by of­fer clini­cians tar­get­ed treat­ment op­tions that are po­ten­tial­ly safer, more ef­fec­tive, and more eas­i­ly de­liv­er­able than their pro­tein-based coun­ter­parts. Both ARMs and SyAMs are adapt­able plat­forms that can be de­ployed against can­cer and in­fec­tious dis­eas­es. [more in­for­ma­tion]
Kriya Therapeutics
The com­pany us­es al­go­rith­mic tools, scal­able in­fras­truc­ture, and pro­pri­e­tary tech­nol­o­gy to op­ti­mize the ef­fi­ca­cy and dura­bil­i­ty of our gene ther­a­pies, there­by en­abling health­care in­sti­tu­tions to pro­vide trans­for­ma­tive new treat­ments for high­ly pre­va­lent and se­vere chron­ic dis­eas­es. [more in­for­ma­tion]
KSQ Therapeutics
The com­pany's in­dus­trial­ized func­tio­n­al ge­nomics en­gine uti­l­izes a suite of pro­pri­e­tary CRIS­PR/Cas9 tools that iden­ti­fies nov­el path­ways and tar­gets in­volved in on­col­o­gy and im­muno-on­col­o­gy en­abling clients to un­cov­er nov­el drug tar­gets, mech­anisms for drug ef­fi­ca­cy and iden­ti­fy trans­for­ma­tive sin­gle-agent and com­bi­na­tion ther­a­pies to ben­e­fit pa­tients. [more in­for­ma­tion]
Kuur Therapeutics
Ku­ur Ther­a­peu­tics is com­mitt­ed to trans­form­ing the lives of pa­tients with can­cer and is lead­ing the de­vel­op­ment of off-the-shelf en­gi­neered CAR-NKT cell ther­a­pies. Our ap­proach com­bines the high­ly dif­fer­en­ti­at­ed, na­t­u­ral bi­ol­o­gy of a spe­cif­ic sub­set of cy­to­tox­ic T cells, called na­t­u­ral killer T cells (NKT cells) and in­no­va­tive CAR con­struct en­gi­neer­ing. [more in­for­ma­tion]
Lyndra Therapeutics
The com­pany's plat­form helps in the lin­ear drug re­lease of small molecules and pep­tides for sev­en days or more from each oral­ly ad­min­is­tered cap­sule, en­abling physi­cians to im­prove pa­tient care by im­prov­ing ther­a­peu­tic ef­fi­ca­cy, there­by re­duc­ing side ef­fects and gen­er­at­ing cost-sav­ings. [more in­for­ma­tion]
The com­pany's ther­a­pies are vi­ral can­cer im­munother­a­py en­cod­ing an op­ti­mized ver­sion of CD40 li­gand that treats a broad range of can­cer types such as blad­der can­cer, me­tastat­ic me­lano­ma, lym­pho­ma, lung can­cer, and he­p­a­to­cel­lu­lar car­ci­no­ma, en­abling pa­tients to over­come the re­sis­tance of dis­ease cells to che­mother­a­py. [more in­for­ma­tion]
Neurana Pharmaceuticals
The pri­mary ob­jec­tive of the study was to as­sess the ef­fi­ca­cy of vari­ous dai­ly dos­es of tolperi­sone to de­ter­mine the dose to be used for the planned Phase 3 clin­i­cal pro­gram. Giv­en the pos­i­tive re­sults of the STAR Study, Neu­ra­na plans to conduct an end-of-Phase 2 meet­ing with the FDA in the first quar­ter of 2020 and ini­ti­ate Phase 3 clin­i­cal studies of tolperi­sone lat­er in 2020. [more in­for­ma­tion]
Neurona Therapeutics
Our ini­tial aim is to gen­er­ate ther­a­peu­tic com­po­si­tions of a spe­cif­ic type of nerve cell (or neu­ron) for tar­get­ed de­liv­ery in­to the in­jured ner­vous sys­tem. Based on near­ly two de­cades of re­search, we be­lieve that par­tic­u­lar sub­pop­u­la­tions of neu­rons have the unique abil­i­ty to in­te­grate and re­pair dys­reg­u­lat­ed neu­ral cir­cuits. [more in­for­ma­tion]
NorthSea Therapeutics
First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH (pos­i­tive Ph2b in­ter­im re­sults) and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]
NRx Pharmaceuticals, Inc. [NRXP] $349 MM MCap
Lead­ing Re­lief Ther­a­peu­tics Ph 2 trial of Avip­tadil to treat COVID-19 in­duced ARDS in the US. In Phase 3 with read­out ex­pect­ed mid-Jan­uary 2021. Al­so de­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. NRX-101 is in Ph 2b/3 de­vel­op­ment, (Break­through Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. [more in­for­ma­tion]
In a broad strate­g­ic al­liance with MD An­der­son Can­cer Cen­ter, On­coRe­sponse de­ploys a pro­pri­e­tary B-cell dis­cov­ery plat­form to iden­ti­fy and de­vel­op nov­el ther­a­peu­tics tar­get­ing the tu­mor mi­croen­vi­ron­ment. [more in­for­ma­tion]
Palladio Biosciences
Has been merged with Centes­sa Phar­ma­ceu­ti­cals Limit­ed De­vel­op­er of nov­el ther­a­peu­tics in­tend­ed to de­vel­op medicines for or­phan drug dis­eas­es of the kid­ney. The com­pany's of­fer­ings in­clude de­vel­op­ing treat­ments for Po­ly­cys­tic Kid­ney Dis­ease (PKD) which cause nu­mer­ous fluid-filled cysts to grow in both kid­neys, en­abling doc­tors to pre­vent the pro­gres­sion of PKD. [more in­for­ma­tion]
Pear Therapeutics
The com­pany's plat­form com­bines nov­el dig­i­tal in­ter­ven­tions with drugs to en­hance ef­fi­ca­cy well be­yond any­thing that is com­mer­cial­ly avai­l­able or in clin­i­cal de­vel­op­ment, en­abling clients to get bet­ter out­comes for pa­tients, smarter en­gage­ment and track­ing tools for clini­cians and cost-ef­fec­tive ser­vices for pay­ors. [more in­for­ma­tion]
Pipeline Therapeutics
The com­pany al­so has a port­fo­lio of pro­grams ad­dress­ing a range of neu­ro­log­i­cal di­s­or­ders, in­clud­ing de­vel­op­ment can­di­date PIPE-307 which is fo­cused on re­myeli­na­tion to treat mul­ti­ple scle­ro­sis. [more in­for­ma­tion]
Portal Instruments
The com­pany's in­jec­tors use nee­dle-free tech­nol­o­gy that ad­min­is­ters a nar­row stream of med­i­ca­tion, about the size of a strand of hair, through the skin in less than half a se­cond, en­abling physi­cians to de­liv­er drugs to their pa­tients through the skin with­out a nee­dle at spe­cif­ic depths and vol­umes. [more in­for­ma­tion]
R2 Technologies
Head­quar­tered in Sil­i­con Val­ley, R2 fo­cus­es on the de­vel­op­ment and com­mer­cial­iza­tion of ground­break­ing tech­nolo­gies for aes­thet­ic providers and con­sumers. Based on the li­censed ex­clu­sive in­tel­lec­tu­al prop­er­ty from Mas­sachusetts Gen­er­al Hos­pi­tal to mo­d­u­late me­lanin pro­duc­tion, R2 Tech­nolo­gies was found­ed in 2014 by Pansend Life Sci­ences and Blos­som In­no­va­tions. [more in­for­ma­tion]
Sensei Biotherapeutics
The com­pany is us­ing its pro­pri­e­tary drug dis­cov­ery plat­form, called SPIR­IT, to dis­cov­er and de­vel­op both vaccines and T-cell ther­a­pies, in­clud­ing SN­S301, its clin­i­cal stage can­cer vaccine, and SNS-723, its cell ther­a­py pro­gram in pre­clin­i­cal de­vel­op­ment for solid tu­mors and he­ma­to­log­i­cal can­cers. [more in­for­ma­tion]
Senti Bio
De­vel­op­er of nov­el ther­a­peu­tics de­signed to de­liv­er more pre­cise treat­ments. The com­pany's ther­a­peu­tics spe­cial­ize in cell en­gi­neer­ing and bi­o­log­i­cal pro­gram­ming to build the fu­ture of gene and cell based ther­a­pies, en­abling pa­tients to get live sav­ing treat­ments at an af­ford­able cost. [more in­for­ma­tion]
Teon Therapeutics
Pipe­line of next-gen­er­a­tion can­cer ther­a­peu­tics tar­get­ing GPCRs in­clud­ing a high­ly-spe­cif­ic A2B an­ta­g­on­ist and EP4 an­ta­g­on­ist, both slat­ed to en­ter Phase 1b trials in 2021. [more in­for­ma­tion]
Viracta Therapeutics, Inc.
Virac­ta is a clin­i­cal-stage drug de­vel­op­ment com­pany fo­cused on ad­vanc­ing nov­el epi­ge­net­ic ther­a­peu­tics de­rived from its pro­pri­e­tary Kick & Kill ther­a­peu­tic ap­proach to ben­e­fit pa­tients with vi­ral-as­so­ci­at­ed can­cers and other se­ri­ous dis­eas­es. Virac­ta plans to en­ter in­to ad­di­tio­n­al ge­o­graph­ic and com­bi­na­tion ther­a­py part­n­er­ships. [more in­for­ma­tion]
Vor Biopharma
Th­ese eH­SCs lead to gen­er­a­tions of new healthy blood cells and the eH­SCs can cont­in­ue func­tion­ing nor­mal­ly be­cause they are ef­fec­tive­ly hid­den from the ther­a­pies that tar­get the rel­e­vant pro­tein. In con­trast, dis­eased cells re­tain the tar­get pro­tein and are vul­n­er­able to at­tack. [more in­for­ma­tion]
Xilio Therapeutics
Xilio Ther­a­peu­tics is a biotech­nol­o­gy com­pany ad­vanc­ing next-gen­er­a­tion can­cer im­munother­a­pies de­signed to im­prove pa­tient out­comes by un­leash­ing the pow­er of the im­mune sys­tem se­lec­tive­ly at the site of the tu­mor. [more in­for­ma­tion]
Zikani Therapeutics
Zikani Ther­a­peu­tics is us­ing its in­no­va­tive chem­istry tech­nol­o­gy plat­form to de­vel­op nov­el Ri­bo­some Mo­d­u­lat­ing Agents (RMAs). Zikani’s TUR­BO-ZM plat­form al­lows rapid syn­th­e­sis of nov­el com­pounds that can be op­ti­mized to mo­d­u­late the hu­man ri­bo­some in a dis­ease spe­cif­ic man­n­er. [more in­for­ma­tion]